IRCCS Istituto Nazionale Tumori Fondazione Pascale

25 trials 17 recruiting Academic / non-commercial

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

17 Recruiting

4 Completed trials

2 Countries active

42 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II/III: 2 Phase II: 17 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 4 Ovarian cancer recurrent 2 ARID1A gene mutation 1 Lung cancer metastatic 1 Ovarian cancer 1 Rectal cancer 1 Gastrooesophageal cancer 1 Prostate cancer 1 Oropharyngeal cancer 1 Pancreatic carcinoma 1 Cholangiocarcinoma 1 Oral neoplasm 1

Top IMPs

OXALIPLATIN 4 FLUOROURACIL 3 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 3 OLAPARIB 3 BLEOMYCIN SULFATE 2 CALCIUM LEVOFOLINATE 2 CISPLATIN 2 PACLITAXEL ALBUMIN-BOUND 2 PANITUMUMAB 2 AFLIBERCEPT 1 BEVACIZUMAB 1 CALCIUM LEVOFOLINATE PENTAHYDRATE 1

All trials — page 2

25 total

Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle… Ended

2025-520735-16-00 Phase II 1 country BLEOMYCIN SULFATE; CARBOPLATIN; CISPLATIN; FLUOROURACIL

Showing 25–25 of 25 trials

← All sponsors A–Z